The impetus for using Nrp1 antibody blockade in cancer derives from its direct role in tumor cell survival and proliferation [38], [39], its role in VEGF ligand-mediated angiogenesis [15], [40], [41], [42], and also in the augmentation of Treg suppression [16], [19], [32]. This evidence concerns the gene VEGFA and cancer.